BioMarin Pharmaceutical Inc. (BMRN)’s Financial Results Comparing With Gemphire Therapeutics Inc. (NASDAQ:GEMP)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Gemphire Therapeutics Inc. (NASDAQ:GEMP) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioMarin Pharmaceutical Inc. 1.50B 11.33 124.95M -0.50 0.00
Gemphire Therapeutics Inc. N/A 0.00 26.73M -2.11 0.00

Demonstrates BioMarin Pharmaceutical Inc. and Gemphire Therapeutics Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical Inc. -8.33% -4.4% -2.7%
Gemphire Therapeutics Inc. 0.00% -211% -99.4%

Liquidity

The Current Ratio of BioMarin Pharmaceutical Inc. is 2.9 while its Quick Ratio stands at 2.3. The Current Ratio of rival Gemphire Therapeutics Inc. is 3.3 and its Quick Ratio is has 3.3. Gemphire Therapeutics Inc. is better equipped to clear short and long-term obligations than BioMarin Pharmaceutical Inc.

Analyst Ratings

BioMarin Pharmaceutical Inc. and Gemphire Therapeutics Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BioMarin Pharmaceutical Inc. 0 3 2 2.40
Gemphire Therapeutics Inc. 0 0 0 0.00

BioMarin Pharmaceutical Inc. has a 19.42% upside potential and an average price target of $113.75.

Institutional and Insider Ownership

BioMarin Pharmaceutical Inc. and Gemphire Therapeutics Inc. has shares owned by institutional investors as follows: 0% and 28.1%. BioMarin Pharmaceutical Inc.’s share owned by insiders are 0.5%. Insiders Competitively, owned 23.61% of Gemphire Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioMarin Pharmaceutical Inc. -2.29% -5.28% -3.77% 4.5% 15.98% 5.23%
Gemphire Therapeutics Inc. -9.4% -24.82% -49.76% -83.74% -86.36% -86.66%

For the past year BioMarin Pharmaceutical Inc. had bullish trend while Gemphire Therapeutics Inc. had bearish trend.

Summary

BioMarin Pharmaceutical Inc. beats on 7 of the 10 factors Gemphire Therapeutics Inc.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH). It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. The company is headquartered in Livonia, Michigan.